Nuvation Bio announced that data from its critical phase 2 Trust-I study on the Ros1 inhibitor Taletrectinib has been published in the “Journal of Clinical Oncology” and reported at the 2024 Asco Annual Meeting
Nuvation Bio宣布其在研Ros1抑制剂Taletrectinib的关键性2期Trust-I研究的数据已发表在《临床肿瘤学杂志》上并在2024年Asco年会上进行了报道
Nuvation Bio announced that data from its critical phase 2 Trust-I study on the Ros1 inhibitor Taletrectinib has been published in the “Journal of Clinical Oncology” and reported at the 2024 Asco Annual Meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.